-
Reviewed by Brunilda Nazario, MD on October 21, 2011
-
Sources:
1. Bernstein, CN, Leslie, WD, Leboff, MS. AGA technical review on osteoporosis in gastrointestinal diseases. Gastroenterology, 2003; 124(3):795-841.
2. Lichtenstein, GR, Abreu, MT, Cohen, R, Tremaine, W. American Gastroenterological Association Institute medical position statement on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology, 2006; 130(3):935-939.
3. Lichtenstein, GR, Abreu, MT, Cohen, R, Tremaine, W. American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology, 2006; 130(3):940-987.
4. American Gastroenterological Association medical position statement: guidelines on osteoporosis in gastrointestinal diseases. Gastroenterology, 2003; 124(3):791-794.
5. Vestergaard, P. Bone loss associated with gastrointestinal disease: prevalence and pathogenesis. Eur J Gastroenterol Hepatol, 2003; 15(8):851-856.
6. Garcia-Rodriguez, LA, Ruigomez, A, Panes, J. Acute gastroenteritis is followed by an increased risk of inflammatory bowel disease. Gastroenterology, 2006; 130(6):1588-1594.
7. Tindall, WN. New approaches to adherence issues when dosing oral aminosalicylates in ulcerative colitis. Am J Health Syst Pharm, 2009; 66(5):451-457.
8. Seres, G, Kovacs, Z, Kovacs, Z, et al. Different associations of health related quality of life with pain, psychological distress, and coping strategies in patients with irritable bowel syndrome and inflammatory bowel disorder. J Clin Psychol Med Settings, 2008; 15(4):287-295.
9. Pallis, AG, Mouzas, IA. Instruments for quality of life assessment in patients with inflammatory bowel disease. Dig Liver Dis, 2000; 32(8): 682-688.
Health Solutions From Our Sponsors
©2005-2013 WebMD, LLC. All rights reserved.
WebMD does not provide medical advice, diagnosis or treatment. See additional information.